Payment overview · 2025
General Payments
$927.61
48 reported records · 12 companies
Healthcare provider profile · identity verified
Neha Tyagi
Allopathic & Osteopathic Physicians|Family Medicine · CHICO, CA · NPI 1518372986
Verified facts
What the public records show
CMS Open Payments records show Neha Tyagi received $927.61 in general payments during 2025 across 48 reported records.
ABBVIE INC. accounted for 36.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $341.27 | 36.8% | 26 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $197.55 | 21.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.18 | 9.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.85 | 8.1% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $44.35 | 4.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.04 | 4.1% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $35.24 | 3.8% | 2 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $30.35 | 3.3% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $26.26 | 2.8% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.37 | 1.8% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $16.21 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.94 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $927.61 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $324.44 | 25 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $308.73 | 24 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $123.30 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $92.18 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $92.18 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $74.85 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $74.25 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $44.35 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.04 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $35.24 | 2 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $30.35 | 2 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $30.35 | 2 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $30.35 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $26.26 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 126 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
126 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 334 | 139 |
| Lisinopril | Lisinopril | 228 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 181 | 75 |
| Metformin Hcl | Metformin Hcl | 169 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 57 |
| Omeprazole | Omeprazole | 141 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 136 | 59 |
| Gabapentin | Gabapentin | 136 | 56 |
| Ozempic | Semaglutide | 126 | 39 |
| Losartan Potassium | Losartan Potassium | 122 | 60 |
| Montelukast Sodium | Montelukast Sodium | 105 | 43 |
| Furosemide | Furosemide | 99 | 45 |
| Potassium Chloride | Potassium Chloride | 83 | 31 |
| Famotidine | Famotidine | 80 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 33 |
| Simvastatin | Simvastatin | 80 | 34 |
| Farxiga | Dapagliflozin Propanediol | 77 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 33 |
| Baclofen | Baclofen | 75 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 38 |
| Trazodone Hcl | Trazodone Hcl | 61 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 56 | 26 |
| Jardiance | Empagliflozin | 52 | 17 |
| Ibuprofen | Ibuprofen | 51 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 50 | 23 |
| Alendronate Sodium | Alendronate Sodium | 48 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 20 |
| Allopurinol | Allopurinol | 46 | 17 |
| Carvedilol | Carvedilol | 46 | 20 |
| Eliquis | Apixaban | 43 | 14 |
| Buspirone Hcl | Buspirone Hcl | 41 | 13 |
| Ezetimibe | Ezetimibe | 41 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 14 |
| Januvia | Sitagliptin Phosphate | 40 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 16 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 12 |
| Propranolol Hcl | Propranolol Hcl | 30 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Nystatin | Nystatin | 27 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 26 | 12 |
| Atenolol | Atenolol | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | 12 |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $927.61 · 48 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, APTIMA, BREZTRI, COMIRNATY, CREON, DUPIXENT, Dexcom G6 Transmitter, Grastek, INJECTAFER, LINZESS, NUZYRA, Odactra, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, Ragwitek, Rybelsus, TRUMENBA, The Cologuard Plus Collection Kit, UBRELVY, Xhance | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error